Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
PaperCitations, authors & open-access status
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 967 citations, 2019 year and closed oa status.
967
Citations
2019
Year
closed
OA Status